Alternating Hemiplegia of Childhood FoundationAlternating Hemiplegia of Childhood Foundation

Donate/

Menu

  • Home
  • About AHC
    • What is AHC
    • AHCF Can Help
    • Genetic Testing for AHC
    • Medication
    • What AHC Looks Like
    • Patient Care
    • Family Care
      • ABLE Act
    • Compounding Conditions
    • Glossary
  • Research
    • Research Projects
      • AAV Project
      • Natural History Database Project
    • Research Studies
    • Databases
    • AHC Bibliography
    • AHC in Charts
    • Grant Requests
  • The Foundation
    • Overview
    • Board of Directors
    • Medical Advisory Board
    • Policies and Info
      • Website Term & Conditions
      • Copyright Statement
      • Trademarks & Servicemarks
      • Privacy Policy
      • Conflict of Interest Policy
      • Financials
  • Fundraising
    • Contribute
    • Fundraising Overview
      • Media Resources
    • Where Funds are Directed
    • Hosting an Event
    • Fundraising Ideas
    • Fundraising Resources
  • Community
    • Engage
    • Webinar Series
    • Get Involved
      • Volunteer
      • Fundraise
      • Contribute
    • Who is AHC?
    • Family Meetings
      • New Jersey 2018
      • Indianapolis 2016
    • AHC Organizations
  • Resources
    • AHCF Can Help
    • Webinar Series
    • Fundraising Resources
    • Media Resources
    • Glossary
    • Helpful Links
    • Site Map
  • Contact us!

Coalition Letter for Advancing Targeted Therapies for Rare Diseases

 Posted on October 27, 2015 by jmarsz

 Leave a Comment

As a member of NORD we are proud to have joined forces with 75 other rare disease organizations and signed the “Coalition Letter for Advancing Targeted Therapies for Rare Diseases Act” Click here to view PDF of the Letter. This bill is a result of the efforts of Parent Project Muscular Dystrophy (PPMD), the Muscular Dystrophy Association (MDA), Duchenne Alliance, and more within the rare disease patient advocacy community. This legislation clarifies FDA’s existing authority to leverage data previously used in the approval of a targeted drug when approving a new therapy that “incorporates or utilizes the same or similar genetically targeted technology, or the same variant protein targeted technology”. This is particularly important to drug development for patients with diseases that contain various genetic sub-populations. This is also important for diseases that may be genetically related to other diseases, and could potentially benefit from drug development in those other diseases. The bill language for S.2030 can be found here: https://www.congress.gov/bill/114th-congress/senate-bill/2030/text
Facebook0
Twitter0
Google+0
LinkedIn0
Pinterest0
Tweet

 Category: Foundation Updates, News      Tags:

← Impact Statement Published
October Boosletter →

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

A donation now can change the future for these children and families, before it is too late.

Become a fundraiser with our convenient peer-to-peer platform.

Foundation Updates
  • Race for hope
  • New Race Gear
  • Let’s Party
  • We need you!
  • RACE to END AHC
GreatNonprofits
Contact Us
Alternating Hemiplegia of Childhood Foundation 2000 Town Center Suite 1900 Southfield, MI 48075
(313) 663-7772
Say what? Translate here.
Newsletter Subscription
Subscribe to our Email Newsletter
Our Partners
We’re Doing All Right!
Alternating Hemiplegia of Childhood Foundation Inc Nonprofit Overview and Reviews on GreatNonprofits
Volunteer. Donate. Review.

Copyright © 2023 · All Rights Reserved · Alternating Hemiplegia of Childhood Foundation